A phase Ib/II study of second-line therapy with panitumumab, irinotecan, and everolimus (PIE) in metastatic colorectal cancer with KRAS wild type (WT).

被引：0
|
作者：
Townsend, A. R.
Pirc, L.
Hardingham, J.
Karapetis, C. S.
Tebbutt, N. C.
Singhal, N.
Price, T. J.
机构：
[1] Queen Elizabeth Hosp, Adelaide, SA, Australia
[2] Basil Hetzel Inst, Adelaide, SA, Australia
[3] Flinders Med Ctr, Adelaide, SA, Australia
[4] Austin Hosp, Ludwig Oncol Unit, Heidelberg, Vic 3084, Australia
[5] Royal Adelaide Hosp, Adelaide, SA 5000, Australia
[6] Queen Elizabeth Hosp, Woodville, SA 5011, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2011年 / 29卷 / 15期
关键词：
D O I：
10.1200/jco.2011.29.15_suppl.tps162
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS162
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Panitumumab (Pmab) versus cetuximab (Cmab)/irinotecan (Iri) therapy among patients with KRAS wild-type (wt) metastatic colorectal cancer (MCRC).
    Kennecke, Hagen F.
    Chen, Leo
    Blanke, C. D.
    Cheung, Winson Y.
    Schaff, Kimberly
    Speers, Caroline
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (04)
  • [32] Panitumumab In Metastatic Colorectal Cancer with Wild-Type KRAS
    Weber, Juliane
    McCormack, Paul L.
    BIODRUGS, 2008, 22 (06) : 403 - 411
  • [33] A phase II study of panitumumab plus irinotecan for metastatic colorectal cancer with wild KRAS, resistant to fluoropyrimidine, oxaliplatin, and irinotecan in Japanese (OGSG1001).
    Taira, Koichi
    Yoshida, Motoki
    Sugimoto, Naotoshi
    Kii, Takayuki
    Kuwakado, Shin
    Fukunaga, Mutsumi
    Hasegawa, Hiroko
    Kato, Takeshi
    Miyake, Yasuhiro
    Hata, Taishi
    Tokunaga, Yukihiko
    Takeda, Koji
    Daga, Haruko
    Yoshinami, Tetsuhiro
    Shimokawa, Toshio
    Sakai, Daisuke
    Kurokawa, Yukinori
    Satoh, Taroh
    Tsujinaka, Toshimasa
    Furukawa, Hiroshi
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [34] Randomized phase II study of dual epidermal growth factor receptor inhibition with erlotinib and panitumumab with or without irinotecan as second-line therapy in patients with metastatic colorectal cancer
    Kalyan, Aparna
    Kircher, Sheetal Mehta
    Nimeiri, Halla Sayed
    Wisinski, Kari Braun
    Suh, Jason J.
    Jones, Michael
    Lakhani, Ali R.
    Rademaker, Alfred
    Mulcahy, Mary Frances
    Benson, Al Bowen
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [35] Biweekly Raltitrexed Combined With Irinotecan as Second-Line Therapy for Patients With Metastatic Colorectal Cancer: A Phase II Trial
    Cheng, Ke
    Zhou, Yu-Wen
    Chen, Ye
    Li, Zhi-Ping
    Qiu, Meng
    Liu, Ji-Yan
    CANCER CONTROL, 2022, 29
  • [36] Biweekly Raltitrexed Combined With Irinotecan as Second-Line Therapy for Patients With Metastatic Colorectal Cancer: A Phase II Trial
    Cheng, Ke
    Zhou, Yu-Wen
    Chen, Ye
    Li, Zhi-Ping
    Qiu, Meng
    Liu, Ji-Yan
    CANCER CONTROL, 2022, 29
  • [37] Biweekly Raltitrexed Combined With Irinotecan as Second-Line Therapy for Patients With Metastatic Colorectal Cancer: A Phase II Trial
    Cheng, Ke
    Zhou, Yu-Wen
    Chen, Ye
    Li, Zhi-Ping
    Qiu, Meng
    Liu, Ji-Yan
    CANCER CONTROL, 2022, 29
  • [38] A phase I study of Panitumumab with Irinotecan and S-1 (PanSIR) as first line therapy for Kras wild type patients with advanced colorectal cancer
    Goto, A.
    Ichikawa, Y.
    Tokuhisa, M.
    Kobayashi, N.
    EUROPEAN JOURNAL OF CANCER, 2015, 51 : S373 - S373
  • [39] A 3-weekly schedule of irinotecan and panitumumab for wild-type KRAS metastatic colorectal cancer
    Hansen, Torben Frostrup
    Andersen, Rikke Fredslund
    Pallisgaard, Niels
    Spindler, Karen-Lise Garm
    Ploen, John
    Keldsen, Nina
    Lindebjerg, Jan
    Sorensen, Flemming Brandt
    Jakobsen, Anders
    COLORECTAL CANCER, 2014, 3 (02) : 135 - 145
  • [40] Phase II Study of Irinotecan Plus Panitumumab as Second-Line Therapy for Patients with Advanced Esophageal Adenocarcinoma
    Yoon, Harry
    Karapetyan, Lilit
    Choudhary, Anita
    Kosozi, Ramla
    Bali, Gurvinder Singh
    Zaidi, Ali H.
    Atasoy, Ajlan
    Forastiere, Arlene A.
    Gibson, Michael K.
    ONCOLOGIST, 2018, 23 (09): : 1004 - +
12345